Search

Displaying results 9681 - 9690 of 10000 in total
  1. Drug

    Mipicoledine

    go.drugbank.com/drugs/DB15075
    Investigational

    Mipicoledine is under investigation in clinical trial NCT01048008 (Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer).

    Categories: P-glycoprotein substratesSynonyms: (3.BETA.)-CHOLEST-5-EN-3-YL 3,5-DICHLORO-2-METHOXY-6-(TRICHLOROMETHYL)PYRIDIN-4-YL CARBONATE, CHOLEST-5-EN-3-OL (3.BETA.)-, 3-(3,5-DICHLORO-2-METHOXY-6-(TRICHLOROMETHYL)-4-PYRIDINYL CARBONATE)
  2. Drug

    Dexpramipexole

    go.drugbank.com/drugs/DB15130
    Investigational

    trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  3. Drug

    2-Hydroxylpropyl-beta-cyclodextrin

    go.drugbank.com/drugs/DB15146
    Investigational

    Adrabetadex is under investigation in clinical trial NCT03887533 (Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1).

    Categories: Compounds used in a research, industrial, or household settingSynonyms: 2-Hydroxypropyl-b-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin
  4. Drug

    Dextromethadone

    go.drugbank.com/drugs/DB15198
    Investigational

    Dextromethadone is under investigation in clinical trial NCT00588640 (Study of D-Methadone in Patients With Chronic Pain).

    Synonyms: D-methadone
  5. Drug

    Avapritinib

    go.drugbank.com/drugs/DB15233
    ApprovedInvestigational

    Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal … [A189327] Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464]

    Categories: MATE 2-K Inhibitors, MATE 1 Inhibitors
  6. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    Benzhydrocodone is a benzylic prodrug of hydrocodone.[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.

  7. Drug

    Ferric chloride

    go.drugbank.com/drugs/DB15536
    Approved

    Mixtures: Addamel N, ADDAMEL N
  8. Drug

    Brensocatib

    go.drugbank.com/drugs/DB15638
    Approved

    [A274348] Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibits neutrophil serine proteases, addressing a key driver of this inflammation. … [A274348,A274343] It reduces exacerbations and slows lung function decline, offering a targeted approach to managing NCFB.

    Categories: MATE 1 Inhibitors, MATE 2 InhibitorsSynonyms: (S)-N-((S)-1-Cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo-(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide
  9. Drug

    Cobaltous sulfate

    go.drugbank.com/drugs/DB15760
    Investigational

    Mixtures: NUTRAGESTA ®, NUTRAGESTA ®
  10. Drug

    Navacaprant

    go.drugbank.com/drugs/DB16068
    Investigational

    BTRX-335140 is under investigation in clinical trial NCT04221230 (Study in Major Depressive Disorder With BTRX-335140 vs Placebo).

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring